Lori Troup

Lori is the Director of Analytical Development for Novo Nordisk RNAi CMC Boulder (formerly Dicerna Pharmaceuticals), where her team is responsible for method development and validation activities, drug substance characterization, quality control release and stability studies, and CMC regulatory authoring. Prior to joining Dicerna in 2018, Lori spent 12 years at Agilent Technologies in a number of different roles within Quality Control, Analytical Development, and Analytical Services. Lori holds a B.S. in Chemistry from Abilene Christian University.